This research demonstrates efficient cell sorting and bioorthogonal sensing using magneto-plasmonic nanoparticles, suggesting enhanced diagnostics.
Multifunctional magneto-plasmonic nanoparticles (MP-NPs) are attracting increasing interest for biomedical applications due to their dual magnetic and optical properties. However, existing synthesis protocols for MP-NPs could be limited by harsh conditions or lengthy, complex procedures. These limitations can hinder the development of nanosystems that work effectively in biological dispersion. In this work, we present a flexible nanoplatform for capture and probe applications, based on MP-NPs and bioorthogonal plasmonic nanoparticles (AuNPs). This system enables efficient cell sorting and surface-enhanced Raman scattering (SERS) detection in complex biological media under dynamic conditions. Magnetic Fe₃O₄ nanoclusters were synthesized using a scalable, aqueous Massart-based protocol. These structures were then densely decorated with electrostatically assembled AuNPs, producing magnetically responsive and plasmonically active nanocomposites with high aqueous stability. A polyethylene glycol (PEG) derivative was used for surface functionalization, improving colloidal stability and enabling broad bio-recognition capability. To enhance detection sensitivity and shift the optical response into the near-infrared (NIR) range, bioorthogonal Raman-active gold nanostars (AuNSts) were integrated into a sandwich configuration with the MP-NPs. The system demonstrated selective sorting and sensitive SERS-based identification of cell subpopulation within a heterogeneous sample. Additionally, the integration of the MP-NPs assay into a 3D-printed microfluidic device allowed controlled nanoparticles manipulation using external magnets, enhancing magnetic separation, hot-spots generation, and assay reusability. Overall, these MP-NPs platform combines scalable synthesis, tunable colloidal and surface properties, and compatibility with microfluidic systems. This work lays the foundation for advanced biosensing approaches in lab-on-chip formats for clinical diagnostics and targeted analysis of rare cell populations.
No takes yet. Share an insight, caveat, or question.
Mattii et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: